PMID- 29079735
OWN - NLM
STAT- MEDLINE
DCOM- 20190716
LR  - 20190716
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 7
IP  - 1
DP  - 2017 Oct 27
TI  - SFRP4 gene expression is increased in aggressive prostate cancer.
PG  - 14276
LID - 10.1038/s41598-017-14622-3 [doi]
LID - 14276
AB  - Increased knowledge of the molecular differences between indolent and aggressive 
      prostate cancer is needed for improved risk stratification and treatment 
      selection. Secreted frizzled-related protein 4 (SFRP4) is a modulator of the 
      cancer-associated Wnt pathway, and previously suggested as a potential marker for 
      prostate cancer aggressiveness. In this study, we investigated and validated the 
      association between SFRP4 gene expression and aggressiveness in nine independent 
      cohorts (n = 2157). By differential expression and combined meta-analysis of all 
      cohorts, we detected significantly higher SFRP4 expression in cancer compared 
      with normal samples, and in high (3-5) compared with low (1-2) Grade Group 
      samples. SFRP4 expression was a significant predictor of biochemical recurrence 
      in six of seven cohorts and in the overall analysis, and was a significant 
      predictor of metastatic event in one cohort. In our study cohort, where metabolic 
      information was available, SFRP4 expression correlated significantly with the 
      concentrations of citrate and spermine, two previously suggested biomarkers for 
      aggressive prostate cancer. SFRP4 immunohistochemistry in an independent cohort 
      (n = 33) was not associated with aggressiveness. To conclude, high SFRP4 gene 
      expression is associated with high Grade Group and recurrent prostate cancer 
      after surgery. Future studies investigating the mechanistic and clinical 
      usefulness of SFRP4 in prostate cancer are warranted.
FAU - Sandsmark, Elise
AU  - Sandsmark E
AUID- ORCID: 0000-0002-2175-8027
AD  - Department of Circulation and Medical Imaging, Faculty of Medicine and Health 
      Sciences, NTNU - Norwegian University of Science and Technology, Trondheim, 
      Norway. elise.sandsmark@gmail.com.
FAU - Andersen, Maria K
AU  - Andersen MK
AD  - Department of Circulation and Medical Imaging, Faculty of Medicine and Health 
      Sciences, NTNU - Norwegian University of Science and Technology, Trondheim, 
      Norway.
FAU - Bofin, Anna M
AU  - Bofin AM
AD  - Department of Clinical and Molecular Medicine, Faculty of Medicine and Health 
      Sciences, NTNU - Norwegian University of Science and Technology, Trondheim, 
      Norway.
FAU - Bertilsson, Helena
AU  - Bertilsson H
AD  - Department of Clinical and Molecular Medicine, Faculty of Medicine and Health 
      Sciences, NTNU - Norwegian University of Science and Technology, Trondheim, 
      Norway.
AD  - Department of Urology, St. Olav's Hospital, Trondheim University Hospital, 
      Trondheim, Norway.
FAU - Drablos, Finn
AU  - Drablos F
AD  - Department of Clinical and Molecular Medicine, Faculty of Medicine and Health 
      Sciences, NTNU - Norwegian University of Science and Technology, Trondheim, 
      Norway.
FAU - Bathen, Tone F
AU  - Bathen TF
AUID- ORCID: 0000-0002-8582-6965
AD  - Department of Circulation and Medical Imaging, Faculty of Medicine and Health 
      Sciences, NTNU - Norwegian University of Science and Technology, Trondheim, 
      Norway.
FAU - Rye, Morten B
AU  - Rye MB
AD  - Department of Clinical and Molecular Medicine, Faculty of Medicine and Health 
      Sciences, NTNU - Norwegian University of Science and Technology, Trondheim, 
      Norway.
AD  - Clinic of Surgery, St. Olav's Hospital, Trondheim University Hospital, Trondheim, 
      Norway.
FAU - Tessem, May-Britt
AU  - Tessem MB
AD  - Department of Circulation and Medical Imaging, Faculty of Medicine and Health 
      Sciences, NTNU - Norwegian University of Science and Technology, Trondheim, 
      Norway. may-britt.tessem@ntnu.no.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20171027
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (SFRP4 protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cohort Studies
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prostatic Neoplasms/*metabolism/*pathology
MH  - Proto-Oncogene Proteins/*metabolism
PMC - PMC5660209
COIS- The authors declare that they have no competing interests.
EDAT- 2017/10/29 06:00
MHDA- 2019/07/17 06:00
PMCR- 2017/10/27
CRDT- 2017/10/29 06:00
PHST- 2017/05/15 00:00 [received]
PHST- 2017/10/09 00:00 [accepted]
PHST- 2017/10/29 06:00 [entrez]
PHST- 2017/10/29 06:00 [pubmed]
PHST- 2019/07/17 06:00 [medline]
PHST- 2017/10/27 00:00 [pmc-release]
AID - 10.1038/s41598-017-14622-3 [pii]
AID - 14622 [pii]
AID - 10.1038/s41598-017-14622-3 [doi]
PST - epublish
SO  - Sci Rep. 2017 Oct 27;7(1):14276. doi: 10.1038/s41598-017-14622-3.